INTRODUCTION {#sec1-1}
============

*Withania somnifera* (family Solanaceae) is commonly known as Ashwagandha or Indian Ginseng. It is considered as the King of Herbs due to wide ranging health benefits as documented in the ayurvedic system of medicine in India. Various forms of medication prepared from *W. somnifera* roots are implicated in a vast range of diseases. The root of the plant is extensively used as aphrodisiac, diuretic, astringent, and anthelmintic. The root is prescribed in Ayurveda for snake bite as well as in scorpion sting.\[[@ref1]\] *W. somnifera* improves the cell-mediated immunity helping in body\'s defense against disease. Scientific studies have shown it to be effective in enhancing the physical endurance and alleviating the stress-induced gastric ulcer and hepatotoxicity.\[[@ref2]\] Efficacy of *W. somnifera* in the treatment of several stress-induced diseases like diabetes, hypertension, premature aging, and malignancy have been scientifically evaluated\[[@ref3]\] and support the clinical use of the plant in health-care management. Research findings lend support to the neuroprotective effect of *W. somnifera* as documented in Ayurveda.\[[@ref4][@ref5][@ref6]\] *W. somnifera* is effective against several types of cancer. The detailed mechanism of therapeutic action needs to be addressed. *In vitro* cell culture system is a suitable model to study the molecular targets of antiproliferative compounds.

Viwithan is a standardized hydroalcoholic extract of *W. somnifera* root. Chemically, it contains a high proportion of Withaferin A and moderate amounts of Withanolides A and B together constituting 5% withanolides. In this study, we investigated the effects of Viwithan supplied by the Department of Phytochemistry, Vidya Herbs Pvt. Ltd., against several cancer cell lines such as liver hepatocellular carcinoma (HepG2), Henrietta Lacks cervical carcinoma cells (HeLa), human colorectal carcinoma cell line (HCT-116), Ehrlich-Lettre ascites carcinoma (EAC), and B16F1 cells. Among the cells analyzed, B16F1 murine melanoma cells showed a particularly increased susceptibility to Viwithan. To better understand the mechanisms that mediate Viwithan action, we have evaluated the antiproliferative effect in B16F1 melanoma cells in detail.

MATERIALS AND METHODS {#sec1-2}
=====================

High-performance liquid chromatography analysis {#sec2-1}
-----------------------------------------------

The high-performance liquid chromatography (HPLC) analysis was performed on a C18 column (4.6 mm × 250 mm, Phenomenex Kinetex) at a UV detection of 227 nm (HPLC-LC 2010HT). The isocratic mobile phase of acetonitrile/0.05% phosphoric acid was flowed at 1.5 ml/min through the column.

General {#sec2-2}
-------

Thiazolyl blue tetrazolium blue (MTT), crystal violet staining solution, Dimethyl sulfoxide (DMSO), RNAase A, Proteinase K, Agarose, and bovine serum albumin were purchased from Sigma-Aldrich. All other chemicals used in this study were obtained from Sigma.

Cell culture {#sec2-3}
------------

The cancer cell lines used in the study such as HepG2, HeLa, HCT-116, Ehrlich-Lettre ascites carcinoma (EAC), and B16F1 cells mouse melanoma cell lines were procured from National Centre for Cell Science, Pune. Cells were maintained in Dulbecco\'s minimum essential medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Gibco). The cells were cultured at 37°C in 5% CO~2~ humid atmosphere.

Thiazolyl blue tetrazolium blue assay {#sec2-4}
-------------------------------------

5 × 10^3^ cells were seeded in 100 μl of growth medium in the presence or absence of increasing concentrations of Viwithan in 96-well plates. The cells were cultured at 37°C in 5% CO~2~ for 24, 48, and 72 h. After the stipulated time, MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) solution (0.5 mg/ml) was added to each well and incubated for 3 h. The purple formazan crystals were dissolved in 100 μl of DMSO (HiMedia) by proper mixing.

Crystal violet assay {#sec2-5}
--------------------

Cells were seeded in 96-well plates at a density of 2 × 10^3^ cells/well for 48 h in the presence or absence of different concentrations of Viwithan. After incubation, medium was removed, washed with phosphate-buffer saline (PBS) twice, and then stained with 0.5% crystal violet for 20 min, followed by three rinses in water. Air-dried plates were photographed. For the detection of optical density value, 100 μl of methanol was applied per well to decolorize. Absorbance was read at 570 nm with a microplate reader (Multiskan EX, Thermo scientific). The experiments were repeated three times, each time in triplicate.

Morphological study {#sec2-6}
-------------------

B16F1 cells were treated with different Half maximal inhibitory concentration (IC50) (220, 180 and 100 μg/ml) of Viwithan for 24, 48, and 72 h. Following incubation, the cells were observed under phase contrast microscope. The images were photographed at ×20 magnification using TC capture software (Lawrence and Mayo India (P) Ltd.).

Apoptosis assay with acridine orange/ethidium bromide staining method {#sec2-7}
---------------------------------------------------------------------

B16F1 cells were seeded on to 60 mm dishes at a density of 1.5 × 10^5^ cells and incubated for 24 h. The medium was removed and replaced with medium containing respective IC50 concentrations of Viwithan for 24 and 48 h. After incubation, the medium was removed and cells washed with PBS. A volume of 400 μl of acridine orange/ethidium bromide (AO/EB) dye mix (AO, 100 μg/ml; EB, 100 μg/ml) was added to the dish and cells were observed under fluorescent microscope.

DNA fragmentation assay {#sec2-8}
-----------------------

B16F1 cells were cultured in 6-well plates at a density of 2.5 × 10^5^ cells/well and treated for 24, 48, and 72 h with their respective IC50 concentrations (220, 180, and 100 μg/ml) of Viwithan. After incubation, cells were washed with PBS twice and trypsinized. The cell was lysed in digestion buffer containing 100 mm NaCl, 10 mm Tris, 25 mm EDTA, 0.5% SDS, and 0.1 mg/ml proteinase K. DNA was extracted by phenol/chloroform extraction and was precipitated by ethanol. The precipitated DNA was dissolved in Tris EDTA and treated with RNAase A.

Molecular docking {#sec2-9}
-----------------

AutoDock tools were utilized to generate grids, calculate dock score, and evaluate the conformers of inhibitors bound in the active site of antiapoptotic proteins as targets for antiproliferative activity. AutoDock 4.2 was employed to get docking and binding scores, which is implemented by Lamarckian genetic algorithm method. The ligand molecules, withanolides were designed, and the structure was analyzed using ACD/Chemsketch. The PRODRG server was used to minimize the energy of drug compounds and three-dimensional coordinates were prepared. The protein structure files for B-cell lymphoma 2 (BCL-2), B-cell lymphoma-extra large (BCL-XL), and myeloid cell leukemia 1 (MCL-1) (protein data bank \[PDB\] ID: 1GJH, 2YXJ, and 3MK8) were taken from PDB and edited by removing the hetero atoms using Python molecule viewer. The grid map was centered at particular residues of the protein and was generated with AutoGrid. The Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for minimization, using default parameters.\[[@ref7]\]

Statistical analysis {#sec2-10}
--------------------

The data were expressed as a mean ± standard error of the mean and analyzed by one-way analysis of variance followed by Dunnett\'s *t*-test using GraphPad Prism version 5 (GraphPad Software, Inc., San Diego, California, USA). The data were considered statistically significant at *P* \< 0.05.

RESULTS AND DISCUSSION {#sec1-3}
======================

High-performance liquid chromatography analysis of Viwithan {#sec2-11}
-----------------------------------------------------------

In the present study, Viwithan was characterized for the presence of withanolides using HPLC analysis. The HPLC chromatogram showed the presence of 5% of withaferin A and withanolides A and B \[[Figure 1](#F2){ref-type="fig"}\].

![High-performance liquid chromatography spectra of Viwithan from *Withania somnifera*](PM-13-801-g002){#F2}

Viwithan treatment showed reduction in viability of B16F1 cells {#sec2-12}
---------------------------------------------------------------

MTT assay was performed to evaluate the cytotoxic effect of Viwithan on different human and murine cancer cell lines. The IC50 values recorded were 1830, 968, 2715, and 633 μg/ml, respectively, against HepG2, HeLa, HCT-116, and EAC cells \[[Table 1](#T1){ref-type="table"} and [Figure 2](#F3){ref-type="fig"}\]. Interestingly, we found that Viwithan was more effective against B16F1 mouse melanoma cells with an IC50 value of 220 μg/ml. Hence, we chose B16F1 cells to further validate the cytotoxic potentials of Viwithan.

###### 

The antiproliferation effect of Viwithan on different cancer cell lines

![](PM-13-801-g003)

![Determination of cytotoxicity of Viwithan in different cancer cell lines. Cells were treated with different concentrations of Viwithan for 24 h. Data are expressed as mean ± standard error of the mean of three independent experimental observations (\**P* \< 0.05, \*\**P* \< 0.01, *P* \< 0.001 versus control)](PM-13-801-g004){#F3}

B16F1 cells were treated with different concentrations of Viwithan for 24, 48, and 72 h. A considerable reduction in the cell viability was observed in a dose- and time-dependent manner when compared with the control treated cells. The calculated IC50 values were 220, 180, and 100 μg/ml for 24, 48, and 72 h, respectively \[[Figure 3](#F4){ref-type="fig"}\]. We further confirmed the cytotoxic effect of Viwithan through crystal violet staining at 48 h time point \[[Figure 4](#F5){ref-type="fig"}\]. B16F1 cells were treated with different concentrations of Viwithan; following the incubation time, the cells were stained and the absorbance recorded. IC50 value was recorded to be 180 μg/ml.

![Treatment with different concentrations of Viwithan showed cytotoxic effect on B16F1 cell line at different time points of incubation. Cells were treated with different concentrations of Viwithan for 24, 48, and 72 h. All data are expressed as mean of three independent experimental observations](PM-13-801-g005){#F4}

![Treatment with different concentrations of Viwithan showed cytotoxic effect on B16F1 cell line after 48 h incubation. Cells were treated with different concentrations of Viwithan for 48 h. All data are expressed as mean of three independent experimental observations](PM-13-801-g006){#F5}

Morphological observations of B16F1 cells after treatment with Viwithan {#sec2-13}
-----------------------------------------------------------------------

B16F1 cells were treated with respective IC50 concentrations (220, 180, and 100 μg/ml) of Viwithan for 24, 48, and 72 h, observed under a phase contrast microscope. Morphological alterations were observed in treated cells as compared to control treated. The cells turned round and detached from the surface following treatment with IC50 concentrations of Viwithan. The morphological changes were more significant with an increase in duration of treatment \[[Figure 5](#F6){ref-type="fig"}\]. Further, Viwithan treated cells were observed for the morphological features of apoptosis following a treatment of 24 and 48 h. As shown in [Figure 6](#F7){ref-type="fig"}, the control cells were stained with uniformly green fluorescence and no apoptotic features observed. Viwithan-treated cells were stained as green yellow after 24 h indicating signs of apoptosis. The cells were densely stained as orange after 48 h treatment of Viwithan demonstrating the late apoptosis.

![Morphological changes observed in Viwithan treated B16F1 cells. Cells were treated with 220, 180, and 100 μg/ml of Viwithan for (A) 24, (B) 48, and (C) 72 h, respectively](PM-13-801-g007){#F6}

![Apoptotic changes observed in Viwithan-treated B16F1 cells stained with acridine orange and ethidium bromide. Cells were treated with 220 and 180 μg/ml of Viwithan for (A) 24 and (B) 48 h, respectively](PM-13-801-g008){#F7}

Viwithan treatment induced DNA fragmentation in B16F1 cells {#sec2-14}
-----------------------------------------------------------

DNA fragmentation is one of the hallmark signs of apoptosis. DNA fragmentation assay was carried out in B16F1 cells after 24, 48, and 72 h of treatment with Viwithan. DNA fragmentation was not seen in the control cells and the 24 h treated cells. However, results of the study demonstrated distinct ladder formation in 48 and 72 h of Viwithan treatment as compared to untreated cells \[[Figure 7](#F8){ref-type="fig"}\].

![Viwithan treatment induces DNA fragmentations. L denotes lane in the gel, L1 = 1 kb DNA ladder, L2 = control (0 μg/ml), L3 = 24 h treatment with 220 μg/ml, L4 = 48 h treatment with 180 μg/ml, L5 = 72 h treatment with 100 μg/ml](PM-13-801-g009){#F8}

Viwithan showed inhibitor specificity against antiapoptotic proteins {#sec2-15}
--------------------------------------------------------------------

BCL-2 family of proteins plays a major role in the regulation of apoptosis through interaction with proapoptotic proteins. In the present study, binding affinity of withanolides in Viwithan was studied against antiapoptotic proteins through bioinformatics approach using AutoDock tool. The docking scores revealed that withanolides had favorable interactions with BCL-2, BCL-XL, and MCL-1 proteins \[[Table 2](#T2){ref-type="table"}\]. However, the molecules had a more binding affinity with MCL-1. Comparatively, Withaferin A was predicted to have a profound interact with a binding energy of −6.41 kJ/mol in the MCL-1 active site and had four hydrogen bonds with Gly203, Ser202, Arg207, and Lys208 residues of MCL-1 \[[Figure 8](#F9){ref-type="fig"}\] whereas Withanolide A and B exhibited a slightly lesser binding affinity (−6.19 and −5.78 kJ/mol) with the active site residues. Withaferin A had a strong covalent interaction with MCL-1 as indicated by the bond distance (1.8--2.25 Å) \[[Figure 8](#F9){ref-type="fig"}\].

###### 

Molecular docking score of withanolides with antiapoptotic proteins

![](PM-13-801-g010)

![Molecular docking of Withaferin A and myeloid cell leukemia 1. (a) Molecular surface representation of docked withaferin A with active site of myeloid cell leukemia 1. (b) Cartoon representation of myeloid cell leukemia 1 residues (green) interacting with withaferin A (white). The H-bond interactions are shown as green spheres and the donor-acceptor distance displayed in blue color](PM-13-801-g011){#F9}

Cancer is a complex disease involving malignant tumors causing morbidity and mortality. Progression of cancer is a multistep process leading to the transformation of normal cells into highly malignant derivatives. There are several approaches available in chemotherapy to treat cancer. Chemotherapeutic agents, however, are associated with a lot of side effects. Hence, researchers are searching for safe and nontoxic alternative medicine from natural sources.\[[@ref8][@ref9]\]

*W. somnifera* is one of the important medicinal herbs valued for its vast therapeutic potentials in the ayurvedic system of medicine. Commonly known as "Indian ginseng," *W. somnifera* has been used in formulations to treat conditions such as rheumatoid arthritis, inflammation, constipation, sexual dysfunction, anxiety, and nervous breakdown. *Withania* extracts have been reported to be effective against several types of cancers. Studies revealed that the constituents of genus *Withania* play a significant role in antiproliferative activity against cancer cells such as MCF-7, colon cancer cells, pancreatic, prostate, and fibrosarcoma cells.\[[@ref10][@ref11][@ref12]\] The present study is focused on validating the antiproliferative effects of Viwithan, a standardized *W. somnifera* extract against B16F1 murine melanoma cells.

The cytotoxic effect of Viwithan on different human and murine cancer cell lines was evaluated using MTT assay. We found that Viwithan treatment was particularly effective against B16F1 melanoma cells (IC50: 220 μg/ml) compared to other cell lines tested. We further determined the cytotoxicity of Viwithan against B16F1 cells at varying lengths of time (24, 48, and 72 h). As compared to control cells, there was a significant reduction in cell viability in Viwithan-treated cells. Effect of Viwithan on cell viability was confirmed by crystal violet staining. From these data, we concluded that the cytotoxicity of Viwithan was dose and time dependent in B16F1 cells. The toxic effects of Viwithan can be correlated to the morphological changes in treated cells, as evident from the observations in phase contrast microscopy.

Cancer development and progression in most cases is mediated by the suppression of apoptosis.\[[@ref13]\] AO/EB detects cellular apoptosis as a consequence of differential nuclear staining. The normal and early apoptotic cells are characterized by intact membranes; hence, we considered that AO penetrated these cells fluorescing green when bound to DNA. EB binds to the apoptotic bodies or DNA fragments emitting orange-red fluorescence in the late apoptotic cells.\[[@ref14]\] In our study, followed by treatment with Viwithan for 24 h, the early stage apoptotic cells were marked by yellow-green nuclear staining. Further, AO/EB-stained cells showed asymmetrically localized orange staining after 48 h treatment with Viwithan indicating the signs of late apoptosis.

Cleavage of chromosomal DNA into oligonucleosomal fragments is a hallmark of apoptosis.\[[@ref15]\] We extended the study to check if Viwithan treatment could induce DNA fragmentation in B16F1 cells. Cells were treated with different IC50 concentrations of Viwithan for respective time points (24, 48, and 72 h). The DNA in control and 24 h treated cells remained intact. Interestingly, there was a clear ladder formation in DNA samples from 48 and 72 h treated cells. It can be speculated that the DNA fragmentation seen at 48 and 72 h incubation could be due to a late apoptotic change. Together, microscopic observations and DNA fragmentation assays clearly indicated that Viwithan might initiate late apoptosis in B16F1 cells.

*In silico* docking is a bioinformatics approach used to predict the drug targets and an indispensable tool in the drug discovery. Antiapoptotic proteins are key regulators of mitochondria-dependent apoptosis and major targets for cancer chemotherapy. Virtual screening of potent inhibitors for BCL-2 family proteins enables to search for candidate drugs against cancer. Many researchers have determined the structure-activity relation profile of small molecules as inhibitors of antiapoptotic members from BCL-2 family.\[[@ref16][@ref17]\] In the present study, molecular docking was performed to predict the interaction of withanolides present in Viwithan with the antiapoptotic proteins such as BCL-2, BCL-XL, and MCL-1. In our study, the docking score revealed the favorable interaction between the target proteins and the withanolides. Withaferin A exhibited more binding affinity with all the apoptotic proteins screened. The molecule interacted strongly with the active site residues of MCL-1 having four hydrogen bonds with covalent bonding \[[Figure 8](#F9){ref-type="fig"}\]. The results from *in silico* studies indicate a plausible synergistic effect of withanolides attributing to the Viwithan-induced apoptosis through suppression of intrinsic pathway for carcinogenesis.

Withanolides are the major phytoconstituents present in root and leaves of *W. somnifera*. These secondary metabolites possess immunomodulatory and neuroprotective effects.\[[@ref18][@ref19][@ref20]\] Extracts from different parts of *W. somnifera* with withanolides have been evaluated previously for cancer cell cytotoxicity.\[[@ref21][@ref22]\] In the present study, cytotoxic potentials of Viwithan containing 5% of withanolides were investigated on several cancer cell lines. To conclude, this is the first study reporting the antiproliferative effect of Viwithan against B16F1 melanoma cancer cells. Our data indicate that Viwithan-mediated death of B16F1 cells might be due to the induction of intrinsic pathway of apoptosis. However, to determine the potency of Viwithan, further studies addressing the molecular mechanism of action are to be performed.
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